Why star-studded Peninsula biotech NGM Biopharmaceuticals saw its stock fall more than 70%


Merck & Co. now must decide whether it will exercise an option for the drug.

Previous Fast-growing eastern NC company going public with $600M SPAC deal
Next Labcorp names Google Cloud president to its board